Design, synthesis and efficacy of new small molecule therapeutics to impede myotonic dystrophy

Active Project Grant Awarded Last action

Award ID
R01NS120485
Recipient
Awarding agency
Obligated
$7,407,287

Award facts

Completion date 91% complete
Place of performance
Albany, NY 12222, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Many of the growing family of over 40 neuromuscular and neurodegenerative repeat expansion diseases, including myotonic dystrophy (DM), involve a strong RNA gain-of- function (GOF) mechanism with toxicity induced by expansion rnas. In this mechanism, the expanded rnas sequester RNA binding proteins (rbps) leading to the disruption of multiple downstream RNA processing pathways. The reduction of the expanded rnas to alleviate disease mechanism and downstream pathogenesis is therefore an attractive therapeutic approach. We have previously demonstrated promising small molecule efficacy including: (1) actinomycin d mediated selective reduction of transcription from expanded CTG repeats; (2) microtubule inhibitors mediated selective modulation of toxic CUG RNA levels; and (3) diamidines mediated reduction of toxic rnas. While these results show promise, many of these compounds are toxic and display sub-optimal properties leading US to develop a new set of modified polycyclic compounds (mpcs). These compounds are based on three elements: a heterocyclic core; a benzimidazole side group; and functionalized end groups. Modifying each of these elements provides a large panel of potential compounds to aid in understanding mechanism of action and develop new drug candidates to address the urgent unmet therapeutic need in DM. Preliminary data for two of these mpcs shows robust rescue of splicing in both DM1 and DM2 cell lines in the nanomolar range with little associated toxicity or effects on cell viability as well as rescue of MIS-splicing in 2 independent DM mouse models. In this proposal, we will use parallel in vitro and in vivo design-model-test cycles to systematically modify and evaluate compounds by focusing on replacement, testing and refinement of the three MPC elements (core, side and end groups). These data will provide a better understanding of their mechanism of action and be followed by testing of their therapeutic potential in DM patient-derived cell lines and animal models. The successful completion of this project will provide a new class of therapeutic small molecules, a better understanding of their mechanism of action and in vivo data from multiple animal models supporting their future therapeutic potential. Taken together this information will address the large unmet need for therapeutic approaches for DM and provide supporting data towards future clinical studies.

Transactions

Action Obligated Date
Amendment $13,263
Amendment $502,351
Amendment $502,351
Amendment $69,192
Amendment $69,192
Amendment $425,205
Amendment $425,205
Amendment $33,606
Amendment $33,606
Amendment $69,192
Amendment $69,192
Amendment $69,192
Amendment $13,694
Amendment $13,694
Amendment $13,694
Amendment $432,082
Amendment $432,082
Amendment $432,082
Amendment $45,776
Amendment $45,776
Amendment $45,776
Amendment $55,928
Amendment $55,928
Amendment $55,928
Amendment $488,445
Amendment $488,445
Amendment $488,445
Amendment $488,445
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $509,840
Amendment $509,840
Original award $509,840
Show all 35

Subawards

Subrecipient Amount Awarded
The University Of Osaka Scope of Work (Osaka) Many of the growing family of over 40 neuromuscular and neurodegenerative repeat expansion diseases, including myotonic dystrophy (DM),… $200,900

Quick answers

Who received award R01NS120485?

R01NS120485 was awarded to The Research Foundation For The State University Of New York by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on May 1, 2022.

How much is award R01NS120485 worth?

$7,407,287 has been obligated on R01NS120485.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login